The Technology Development Board (TDB) is backing a game-changing project by Nitika Pharmaceutical Specialities Pvt. Ltd. in Nagpur to produce complex pharmaceutical excipients locally. Supported by the Department of Science and Technology, this effort aims to make India’s pharmaceutical industry less dependent on imports and strengthen its position as a global healthcare leader.
Excipients are like the behind-the-scenes helpers in medicines. They don’t treat you, but they make sure drugs work properly by keeping them stable and helping your body absorb them. With TDB’s support, Nitika is set to use cutting-edge tech to make these high-quality excipients locally. This is a huge step toward India’s goal of becoming self-sufficient, or “Atma Nirbhar,” in pharmaceuticals, ensuring we’ve got a steady supply of what we need.
India’s pharma industry, already worth $55 billion, is expected to grow to $130 billion by 2030. This project will help us stay ahead by using India’s edge—our costs are 30-35% lower than in the US or Europe, thanks to affordable labor and efficient production. It also fits right in with the government’s Production Linked Incentive (PLI) scheme, which has brought in ₹35,000 crore for 55 projects to boost local manufacturing.
Nitika is aiming to produce excipients that meet strict global standards, like those set by the US Food and Drug Administration (FDA) and European regulators. With India now having more FDA-registered generic drug sites (752 as of 2024) than the US, this project will help solidify our nickname as the “pharmacy of the world.”
Also Read: Battery Aadhaar Initiative to Power Circular Economy in India
This move is a win for local innovation, creating skilled jobs in Maharashtra, and cutting down on imports. With India’s pharma exports growing 9% a year—faster than the global average—it’s clear we’re doubling down on leading the world’s healthcare supply chain.
We use cookies to ensure you get the best experience on our website. Read more...
